B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
Access in-depth insight and stay ahead of the market
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview
B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions.
The B-Cell NHL marketed, and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for B-cell NHL. The report also analyzes the clinical and commercial landscapes of B-cell NHL, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Leading Marketed Drugs in B-Cell NHL
A few of the leading marketed drugs in B-Cell NHL are polatuzumab vedotin, Zanubrutinib, Pembrolizumab, and interferon alfa among others. Most marketed drugs for B-cell NHL belong to the class of enzyme inhibitors and protein/peptide inhibitors targeting kinases and proteins like programmed cell death protein 1.
B-Cell NHL Marketed and Pipeline Drugs Market - Top Clinical Trial Sponsors
A few of the top clinical trial sponsors in the B-Cell NHL marketed and pipeline drugs market are F.Hoffmann-La Roche Ltd, University of Texas MD Anderson Cancer Center, National Cancer Institute US, Johnson & Johnson, Gilead Sciences Inc, Celgene Corp, BeiGene Ltd, Novartis AG, and AbbVie Inc among others.
B-Cell NHL Marketed and Pipeline Drugs Market Sponsor Analysis
Buy the full Report for More Molecule Type Insights into the B-Cell NHL Marketed and Pipeline Drugs, Download a Free Report Sample
B-Cell NHL Marketed Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for B-Cell NHL marketed drugs are peptide and peptide inhibitor, genes, nucleic acids & related component inhibitor, protein and peptide activator, enzyme inhibitor, cytotoxic cell, receptor agonist, and receptor antagonist. The peptide and peptide inhibitor segment was the most common mechanism of action for B-Cell NHL marketed drugs.
B-Cell NHL Marketed Drugs Analysis, by Mechanism of Action
Buy the full Report for More MoA Insights into the B-Cell NHL Marketed Drugs, Download a Free Report Sample
B-Cell NHL Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for B-Cell NHL marketed drugs are injection, oral, topical, and suppository. Most conventional marketed drugs available for B-Cell NHL are intravenous therapies.
B-Cell NHL Marketed Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the B-Cell NHL Marketed Drugs, Download a Free Report Sample
B-Cell NHL Marketed Drugs Segmentation by Molecule Type
The key molecule types in the market are small molecule and biologics. The marketed drugs space for B-Cell NHL is dominated by the small molecule segment.
B-Cell NHL Marketed Drugs Analysis, by Molecule Type
Buy the full Report for More Molecule Type Insights into the B-Cell NHL Marketed Drugs, Download a Free Report Sample
B-Cell NHL Pipeline Drugs Segmentation by Mechanism of Action
A few of the key mechanisms of action for B-Cell NHL pipeline drugs are cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, receptor agonist, receptor antagonist, and antigen inhibitor among others. Cytotoxic to cell lead the MoA segment in the B-Cell NHL pipeline drugs market.
B-Cell NHL Pipeline Drugs Analysis, by Mechanisms of Action
Buy the full Report for More MoA Insights into the B-Cell NHL Marketed Drugs, Download a Free Report Sample
B-Cell NHL Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for B-Cell NHL pipeline drugs are injection, oral, topical, inhalational, and suppository. Most pipeline drugs for B-cell NHL are injection therapies followed by oral drugs.
B-Cell NHL Pipeline Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the B-Cell NHL Pipeline Drugs, Download a Free Report Sample
B-Cell NHL Pipeline Drugs Segmentation by Molecule Type
The B-Cell NHL pipeline drugs comprise mostly biologics, small molecules, and oligonucleotide. Most More than 60% of the B-cell NHL pipeline is dominated by biologic molecules.
B-Cell NHL Pipeline Drugs Analysis, by Molecule Types
Buy the full Report for More Molecule Type Insights into the B-Cell NHL Pipeline Drugs, Download a Free Report Sample
B-Cell NHL Marketed and Pipeline Drugs – Deals Landscape
- On 8th Dec 2022, Actinium pharma enters into research agreement with Columbia university.
- On 21 Nov 2022, Opna bio acquires oncology assets from Plexxikon.
Buy the full Report for More Deal Insights into the B-Cell NHL Pipeline Drugs, Download a Free Report Sample
| Key Mechanisms of Action (Marketed) | · Peptide and Peptide Inhibitor
· Genes, Nucleic Acids & Related Component Inhibitor · Protein and Peptide Activator · Enzyme Inhibitor · Cytotoxic Cell · Receptor Agonist · Receptor Antagonist. |
| Key Routes of Administration (Marketed) | · Injection
· Oral · Topical · Suppository |
| Key Molecule Types (Marketed) | · Small Molecule
· Biologics |
| Key Mechanisms of Action (Pipeline) | · Cytotoxic to Cell
· Enzyme Inhibitor · Protein and Peptide Inhibitor · Receptor Agonist · Receptor Antagonist · Antigen Inhibitor |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical · Inhalational · Suppository |
| Key Molecule Types (Pipeline) | · Biologics
· Small Molecule · Oligonucleotide |
| Top Clinical Trial Sponsors | · F.Hoffmann-La Roche Ltd
· University of Texas MD Anderson Cancer Center · National Cancer Institute US · Johnson & Johnson · Gilead Sciences Inc · Celgene Corp |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Segments Covered in the Report
B-Cell NHL Marketed Drugs MoA Outlook
- Peptide and Peptide Inhibitor
- Genes, Nucleic Acids & Related Component Inhibitor
- Protein and Peptide Activator
- Enzyme Inhibitor
- Cytotoxic Cell
- Receptor Agonist
- Receptor Antagonist.
B-Cell NHL Marketed Drugs RoA Outlook
- Injection
- Oral
- Topical
- Suppository
B-Cell NHL Marketed Drugs Molecule Type Outlook
- Small Molecule
- Biologics
B-Cell NHL Pipeline Drugs MoA Outlook
- Cytotoxic to Cell
- Enzyme Inhibitor
- Protein and Peptide Inhibitor
- Receptor Agonist
- Receptor Antagonist
- Antigen Inhibitor
B-Cell NHL Pipeline Drugs RoA Outlook
- Injection
- Oral
- Topical
- Inhalational
- Suppository
B-Cell NHL Pipeline Drugs Molecule Type Outlook
- Biologics
- Small Molecule
- Oligonucleotide
Scope
GlobalData’s B-Cell NHL Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combine data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the B-Cell NHL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global B-Cell NHL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Players
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for B-Cell NHL marketed drugs?
A few of the key mechanisms of action for B-Cell NHL marketed drugs are peptide and peptide inhibitor, genes, nucleic acids & related component inhibitor, protein and peptide activator, enzyme inhibitor, cytotoxic cell, receptor agonist, receptor antagonist.
-
What are the key routes of administration for B-Cell NHL marketed drugs?
The key routes of administration for B-Cell NHL marketed drugs are injection, oral, topical, and suppository.
-
What are the key molecule types for B-Cell NHL marketed drugs?
The key molecule types for B-Cell NHL marketed drugs are small molecule and biologics.
-
What are the key mechanisms of action for B-Cell NHL pipeline drugs?
A few of the key mechanisms of action for B-Cell NHL pipeline drugs are cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, receptor agonist, receptor antagonist, and antigen inhibitor.
-
What are the key routes of administration for B-Cell NHL pipeline drugs?
The key routes of administration for B-Cell NHL pipeline drugs are injection, oral, topical, suppository, and inhalational.
-
What are the key molecule types for B-Cell NHL pipeline drugs?
The key molecule types in B-Cell NHL pipeline drugs are biologics, oligonucleotide, and small molecule.
-
Who are the top clinical trial sponsors for the B-Cell NHL marketed and pipeline drugs market?
Some of the top clinical trial sponsors for the B-Cell NHL marketed and pipeline drugs market are F.Hoffmann-La Roche Ltd, University of Texas MD Anderson Cancer Center, National Cancer Institute US, Johnson & Johnson, Gilead Sciences Inc, Celgene Corp, BeiGene Ltd, Novartis AG, and AbbVie Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
We are confident about B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape report's unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more B-Cell Non-Hodgkin Lymphoma reports